



Strategic VTE Prevention in Knee and Hip Arthroplasty: Insights into the Heparin-Aspirin Protocol

Isla Greer^{*}

Department of Hematology, Griffith University, Queensland, Australia

ABOUT THE STUDY

Venous Thromboembolism (VTE), encompassing Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), is a significant concern following major orthopedic surgeries like knee and hip arthroplasty. The risk of VTE is particularly high due to factors like immobilization, surgical trauma and patientspecific risk factors. To reduce this risk, anticoagulation protocols are employed. One such protocol is the combined use of heparin and aspirin.

Rationale for VTE prophylaxis

Knee and hip arthroplasty are common procedures performed to alleviate pain and restore function in patients with severe arthritis or joint damage [1]. However, the immobilization and surgical trauma involved increase the risk of VTE. Effective prophylaxis is important to prevent the formation of blood clots that can lead to serious complications, including PE, which can be life-threatening.

Heparin-aspirin protocol: The heparin-aspirin protocol combines the anticoagulant effects of heparin with the antiplatelet properties of aspirin to provide comprehensive VTE prophylaxis. This dual approach targets different pathways in the coagulation process, enhancing the overall effectiveness of prevention strategies.

Heparin: Heparin, an anticoagulant, works by inhibiting thrombin and factor Xa, important components in the clotting cascade [2]. It can be administered in two primary forms:

Unfractionated Heparin (UFH): Administered subcutaneously or intravenously, UFH has a short half-life and requires regular monitoring through activated Partial Thromboplastin Time (aPTT) to ensure therapeutic levels [3].

Low Molecular Weight Heparin (LMWH): LMWH, such as enoxaparin, is preferred due to its more predictable pharmacokinetics, longer half-life and lower risk of bleeding. It is usually administered subcutaneously once or twice daily.

Aspirin: Aspirin is an antiplatelet agent that irreversibly inhibits Cyclooxygenase-1 (COX-1), reducing the formation of thromboxane A2, a potent promoter of platelet aggregation [4]. This mechanism helps prevent the initial stages of clot formation.

Protocol specifics

The heparin-aspirin protocol typically involves:

Preoperative phase: Administration of aspirin (81 mg-325 mg) may begin preoperatively, depending on the patient's risk profile and the surgeon's preference [5].

Immediate postoperative phase: LMWH is often initiated 12-24 h post-surgery, given its ease of administration and lower monitoring requirements. The dosage is adjusted based on the patient's weight and renal function [6].

Maintenance phase: Aspirin is continued postoperatively for a specified duration, often ranging from several weeks to three months, depending on the individual's risk factors and mobility status [7].

Effectiveness

Studies have demonstrated the effectiveness of the heparinaspirin protocol in reducing the incidence of VTE following knee and hip arthroplasty. The dual approach is beneficial for:

Comprehensive coverage: By targeting both the coagulation cascade and platelet aggregation, the protocol provides broader protection against clot formation [8].

Reduced VTE rates: Research has shown a significant reduction in the incidence of DVT and PE in patients receiving combined heparin and aspirin therapy compared to monotherapy or placebo.

Improved outcomes: Effective VTE prophylaxis translates to better postoperative outcomes, reduced hospital stays and lower healthcare costs.

Correspondence to: Isla Greer, Department of Hematology, Griffith University, Queensland, Australia, E-mail: islgreer@unimelb.edu.au

Received: 20-Nov-2024, Manuscript No. OMCR-24-33295; Editor assigned: 22-Nov-2024, PreQC No. OMCR-24-33295 (PQ); Reviewed: 09-Dec-2024, QC No. OMCR-24-33295; Revised: 16-Dec-2024, Manuscript No. OMCR-24-33295 (R); Published: 23-Dec-2024, DOI: 10.35248/2161-0533.24.13.409

Citation: Greer I (2024). Strategic VTE Prevention in Knee and Hip Arthroplasty: Insights into the Heparin-Aspirin Protocol. Orthop Muscular Syst. 13:409.

Copyright: © 2024 Greer I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Considerations and potential complications

While the heparin-aspirin protocol is effective, several considerations must be addressed to optimize patient safety and outcomes:

Bleeding risk: Both heparin and aspirin increase the risk of bleeding. Close monitoring of coagulation parameters and patient symptoms is necessary, especially in those with a history of bleeding disorders or concurrent use of other anticoagulants [9].

Patient selection: Individual risk factors, such as age, renal function, history of VTE and comorbidities, should guide the choice and dosage of anticoagulation therapy.

Adherence to protocol: Ensuring patient adherence to the prescribed regimen is important for effective VTE prevention. Education on the importance of medication compliance and recognition of potential side effects is vital.

Monitoring and adjustment: Regular follow-up and potential adjustments to the regimen based on patient response and any adverse effects are necessary to maintain therapeutic efficacy and safety [10].

The heparin-aspirin protocol offers an effective strategy for VTE prevention in patients undergoing knee or hip arthroplasty. By combining the anticoagulant properties of heparin with the antiplatelet effects of aspirin, this approach provides comprehensive protection against clot formation, enhancing patient outcomes and reducing postoperative complications. Careful patient selection, adherence to the protocol and vigilant monitoring are essential to optimize the benefits of this combined therapy.

REFERENCES

- Wu L, Ling Z, Feng X, Mao C, Xu Z. Herb medicines against osteoporosis: Active compounds & relevant biological mechanisms. Curr Top Med Chem. 2017;17(15):1670-1691.
- Liu YM, Lin IJ, Huang CW, Chien RC, Mau CZ, Mau JL. Effect of ethanolic extracts from Taiwanofungus camphoratus and T. salmoneus (Agaricomycetes) mycelia on osteoporosis recovery. Int J Med Mushrooms. 2020;22(3):277-287.
- 3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
- 4. Petracek LS, Eastin EF, Rowe IR, Rowe PC. Orthostatic intolerance as a potential contributor to prolonged fatigue and inconsistent performance in elite swimmers. BMC Sports Sci Med Rehabil. 2022;14(1):139.
- Rossi LA, Molina Romoli AR, Bertona Altieri BA, Burgos Flor JA, Scordo WE, Elizondo CM. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2017;25(10): 3319-3325.
- Lee KS, Wilson JJ, Rabago DP, Baer GS, Jacobson JA, Borrero CG. Musculoskeletal applications of platelet-rich plasma: Fad or future?. AJR Am J Roentgenol. 2011;196(3):628-636.
- Laudy ABM, Bakker EWP, Rekers M, Moen MH. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: A systematic review and meta-analysis. Br J Sports Med. 2015;49(10): 657-672.
- 8. Etulain J. Platelets in wound healing and regenerative medicine. Platelets. 2018;29(6):556-568.
- 9. Nurden AT, Nurden P, Sanchez M andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:3532-3548.
- Taggart R, Langer MD, Lewis GK. Human factors engineering and testing for a wearable, long duration ultrasound system self-applied by an end user. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:554-557.